POSTER: MDS-249 Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs) | Publicación